Small Mitochondria-Targeting Fluorophore with Multifunctional Therapeutic Activities against Prostate Cancer via the HIF1α/OATPs Pathway
Molecular Pharmaceutics · 2023
DOI: 10.1021/acs.molpharmaceut.3c00621 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Pharmaceutics, 2023. Verfasst von Jing Qin und 8 weiteren Autor:innen. Beteiligte Einrichtung: Division of Cancer Biology, Laboratory Animal Center, Fourth Military Medical University, Xi'an, Shaanxi 710032, China. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Organic Anion Transporters. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Natural Science Foundation of China, Shaanxi Province Innovation Capability Support Plan, Army experimental animal special research plan.
Abstract (Originalsprache)
Prostate cancer (PCa) is considered to be the most prevalent malignancy in males worldwide. Abiraterone is a 17α-hydroxylase/C17, 20-lyase (CYP17) inhibitor that has been approved for use in patients with prostate cancer. However, several negative aspects, such as drug resistance, toxicity, and lack of real-time monitoring of treatment responses, could appear with long-term use. Therefore, the development of anticancer agents with specific targeting to avoid side effects is imperative. Here, we used MHI-148, a type of heptamethine cyanine (HC) near-infrared fluorescence dye (NIRF), as a prototype structure to synthesize two theranostic agents, Abi-DZ-1 and Abi-783. The new compound Abi-DZ-1 retained the excellent photophysical characteristics and NIRF imaging property of MHI-148, and it could preferentially accumulate in prostate cancer cells but not in normal prostate epithelial cells via the HIF1α/organic anion-transporting polypeptides axis. NIRF imaging using Abi-DZ-1 selectively identified tumors in mice bearing PCa xenografts. Moreover, Abi-DZ-1 treatment significantly retarded the tumor growth in both a cell-derived xenograft model and a patient-derived tumor xenograft model. This finding demonstrated that Abi-DZ-1 may hold promise as a potential multifunctional theranostic agent for future tumor-targeted imaging and precision therapy. Constructing theranostic agents using the NIRF dye platform holds great promise in accurate therapy and intraoperative navigation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Cancer Biology, Laboratory Animal Center, Fourth Military Medical University, Xi'an, Shaanxi 710032, China.
- Department of Urology, Xijing Hospital, Fourth Military Medical University, Xi'an, Shaanxi 710069, China.
ORCID-Profile: Changhong Shi
Förderung
- National Natural Science Foundation of China
- Shaanxi Province Innovation Capability Support Plan
- Army experimental animal special research plan
Zitieren
APA
Qin, J., Zhang, C., Zhao, Y., Tan, D., Wu, P., Shui, X., Qin, W., Ge, X., & Shi, C. (2023). Small Mitochondria-Targeting Fluorophore with Multifunctional Therapeutic Activities against Prostate Cancer via the HIF1α/OATPs Pathway. Molecular Pharmaceutics. https://doi.org/10.1021/acs.molpharmaceut.3c00621
Vancouver
Qin J, Zhang C, Zhao Y, Tan D, Wu P, Shui X, et al. Small Mitochondria-Targeting Fluorophore with Multifunctional Therapeutic Activities against Prostate Cancer via the HIF1α/OATPs Pathway. Molecular Pharmaceutics. 2023. doi:10.1021/acs.molpharmaceut.3c00621
BibTeX
@article{Qin2023,
author = {Qin, Jing and Zhang, Caiqin and Zhao, Yong and Tan, Dengxu and Wu, Pengpeng and Shui, Xue and Qin, Weijun and Ge, Xu and Shi, Changhong},
title = {Small Mitochondria-Targeting Fluorophore with Multifunctional Therapeutic Activities against Prostate Cancer via the HIF1α/OATPs Pathway},
journal = {Molecular Pharmaceutics},
year = {2023},
doi = {10.1021/acs.molpharmaceut.3c00621}
}
EUVIMED